



RTP TV

CHRONIC MYELOID LEUKEMIA

Select Publications

Akard LP, Wang YL. **Translating trial-based molecular monitoring into clinical practice: Importance of international standards and practical considerations for community practitioners.** *Clin Lymphoma Myeloma Leuk* 2011;[Epub ahead of print].

Abstract

Boccarani M et al. **Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European Leukemia Net.** *Blood* 2006;108(6):1809-20. **Abstract**

Branford S et al. **Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.** *Blood* 2008;112(8):3330-8. **Abstract**

Cortes J et al. **A phase 1 trial of oral ponatinib (AP24534) in patients with refractory chronic myelogenous leukemia (CML) and other hematologic malignancies: Emerging safety and clinical response findings.** *Proc ASH* 2010;Abstract 210.

Druker BJ et al. **Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.** *N Engl J Med* 2006;355(23):2408-17. **Abstract**

Gambacorti-Passerini C et al. **Bosutinib (BOS) versus imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP CML) in the BELA trial: 18-month follow-up.** *Proc ASCO* 2011;Abstract 6509.

Kantarjian H et al. **Dasatinib or imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Two-year follow-up from DASISION.** *Proc ASCO* 2011;Abstract 6510.

Kantarjian H et al. **Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.** *N Engl J Med* 2010;362(24):2260-70. **Abstract**

Larson RA et al. **Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 24-month follow-up.** *Proc ASCO* 2011;Abstract 6511.

Marin D et al. **Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.** *J Clin Oncol* 2010;28(14):2381-8. **Abstract**

Mauro MJ et al. **Survey of current practices in the management of chronic myeloid leukemia (CML).** *Proc ASCO* 2011;Abstract 6513.

Noens L et al. **Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study.** *Blood* 2009;28;113(22):5401-11. **Abstract**

- O'Brien SG et al. **Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.** *N Engl J Med* 2003;348(11):994-1004. **Abstract**
- Radaelli S et al. **Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.** *J Clin Oncol* 2009;27(3):469-71. **Abstract**
- Radich JP et al. **A randomized phase II trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): The S0325 Intergroup trial.** *Proc ASH* 2011;**Abstract LBA6.**
- Radich JP. **How I monitor residual disease in chronic myeloid leukemia.** *Blood* 2009;114(16):3367-81. **Abstract**
- Saglio G et al. **Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.** *N Engl J Med* 2010;362(24):2251-9. **Abstract**